TargetBeta
MSLN
mesothelin · also CAK1, MPF
2 programs in company-led studies act on MSLN, from 2 companies: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (1 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Anti-mesothelin Antibody-drug Conjugate SGN-MesoC2 | Pfizer | – | phase 1 | 10 running | – | the company's pipeline |
| Autologous IL-2-expressing Anti-mesothelin CAR T-cells OPB-101rule | Outpace Bio | – | phase 1 | 10 running | EGFR, IL2 | NCIt |
Conditions their studies are in
- Carcinoma, Non-Small-Cell Lung, 1 program
- Ovarian Neoplasms, 1 program
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.